Uncategorized

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

by Business Wire • 2022/10/13 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new data on TEPEZZA (teprotumumab-trbw) to be presented at the American Thyroid Association (ATA) 2022.

← MacKenzie Scott $15M Gift to VisionSpring Will Help Unlock $1 Billion in Income for Agricultural Workers and Artisans

GEHA Unveils 2023 Medical and Dental Plan Options for Current and Retired Federal Employees, Retired Military and Their Dependents →

Post navigation